Small-cell lung carcinoma paclitaxel

Levitan N, Dowlati A, Shina D, et al. Multi-institutional phase ITU trial of paclitaxel, cisplatin, and etoposide with concurrent radiation for limited-stage small-cell lung carcinoma. J Clin Oncol 2000 18(5) 1102-1109. 

Sundstrom S, Bremnes R, Aasebo U, et al (2004) Hypofrac-tionated palliative radiotherapy (17 Gy per 2 fractions) in advanced non-small cell lung carcinoma is comparable to standard fractionation for symptom control and survival a national phase 111 trial. J Clin Oncol 22 801-810 Taghian AG, Abi-Raad R, Assaad SI, et al (2005) Paclitaxel decreases the interstitial fluid pressure and improves oxygenation in breast cancers in patients treated with neoadjuvant chemotherapy clinical implications. J Clin Oncol 23 1951-1961... 

Herbst RS, Takeuchi H, Teicher BA. Paclitaxel/carboplatin administration along with antiangiogenic therapy in non-small-cell lung and breast carcinoma models. Cancer Chem Pharm 1998,41 497-504. 

Uses Bevacizumab, in combination with fiuoropyrimidine-based chemotherapy, is indicated for patients with metastatic carcinoma of the colon or rectum [155, 156 ", 157, 158 ] in combination with paclitaxel or docetaxel for first-line treatment of patients with metastatic breast cancer [159, 160 ] in addition to platinum-based chemotherapy, for first-line treatment of patients with unresectable, advanced, metastatic or recurrent non-small cell lung cancer, other than with predominantly squamous cell histology [161, 162 ] and in combination with interferon alfa-2a, for first-line treatment of patients with advanced and/or metastatic renal cell cancer [163, 164. ... 

---